This bill would enact the “New York state kratom consumer protection act” and create a new regulatory framework for kratom and kratom products in New York. It defines kratom, kratom products, kratom processors, retailers, extracts, alkaloids, and several synthetic or semi-synthetic kratom-related compounds. The bill would add kratom to the public health law article that already regulates tobacco products, herbal cigarettes, and smoking paraphernalia, and it would establish product standards, registration requirements, labeling rules, age restrictions, and enforcement provisions.
Under the bill, kratom products could not contain synthesized, semi-synthesized, or synthetic kratom-like compounds, certain levels of 7-hydroxymitragynine, dangerous adulterants, combustible or injectable forms, or child-attractive packaging. Processors would have to register products with the Department of Health and submit documentation including third-party audits, FDA food facility registration, sworn compliance declarations, and certificates of analysis showing compliance with contaminant and solvent standards. Retailers and processors would be prohibited from selling unregistered or noncompliant products, and the department would maintain a public registration database. Labels would have to warn against use by people under 21, pregnant or breastfeeding individuals, note that kratom may be habit forming, include FDA disclaimer language, identify the manufacturer or distributor, and provide serving and ingredient information.
The bill would also create civil and criminal penalties for violations, including fines, stop-sale orders, and multi-year bans on selling kratom products after repeated offenses. Selling kratom to anyone under 21 would be prohibited and could be prosecuted as a misdemeanor or felony for repeat violations. The bill further authorizes the Department of Health to require updated testing after credible complaints and to revoke registrations if testing or payment requirements are not met. In addition, the bill would impose a new tax structure on kratom and kratom products, including a 5 percent excise tax on retail sales, with monthly filing and payment requirements for registered retailers.
The overall sentiment reflected in the available materials is limited because there are no recorded committee transcripts or votes in the provided context. Based on the bill text alone, the measure appears to be framed as a consumer protection and product safety bill rather than a prohibition bill, aiming to regulate kratom through testing, labeling, registration, and age limits. The structure suggests an effort to legitimize a regulated market while reducing risks associated with adulterated or highly potent products.
The main points of contention likely center on whether kratom should be regulated as a consumer product at all, how strict the product limits should be, and whether the tax and registration burdens are appropriate. Potentially controversial provisions include the ban on synthetic and semi-synthetic compounds, the 21-and-over sales restriction, the requirement for independent testing and registration, and the new excise tax. Retailers, processors, and kratom consumers would be the most directly affected parties, while the Department of Health and Tax Department would take on new administrative and enforcement responsibilities.
The bill would amend the Public Health Law to add kratom-specific definitions, product standards, registration requirements, labeling mandates, enforcement powers, and penalties, and it would amend the Tax Law to impose a new tax and excise tax on kratom and kratom products. It would create new duties for the Department of Health to register products, maintain a public database, adopt regulations, and enforce compliance, while also creating new obligations for processors, distributors, retailers, and laboratories that test kratom products. It would affect the sale, distribution, marketing, packaging, and taxation of kratom products in New York and would make violations subject to civil penalties and criminal sanctions.
No committee transcript or vote record is provided, so there is no direct evidence of legislative debate or formal support/opposition in the available context. The bill’s text indicates a generally regulatory, consumer-protection-oriented approach, suggesting proponents likely view it as a way to ensure product safety, transparency, and age restrictions rather than to ban kratom outright. At the same time, the detailed compliance and tax provisions imply that some stakeholders may view it as burdensome or restrictive.
Likely points of contention include the bill’s treatment of kratom as a regulated product versus a substance that should be more tightly restricted, the 21-year-old minimum age for purchase, and the prohibition on synthetic, semi-synthetic, and child-attractive products. Industry participants may object to the registration, testing, labeling, and audit requirements, as well as the civil penalties and multi-year sales bans for violations. Consumer advocates or public health stakeholders may focus on whether the potency limits, contaminant standards, and FDA disclaimer language are strong enough to protect users, while others may question the new 5 percent excise tax and whether it could push sales into unregulated channels.